Article3 Biotech2025
Potato protein hydrolysate (PPH902) exerts anti-lipogenesis and lipolysis-promoting effect by inhibiting adipogenesis in 3T3-L1 adipocytes.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- miR-100-5p Enhances Cell Cycle-Mediated Chemoresistance by Modulating the CTDSPL/pRB/E2F1 Signaling Pathway in Oxaliplatin-Resistant Colorectal Cancer Cells.Oncology research · 2026Article
- The natural compound n-butylidenephthalide suppresses type II ovarian cancer cell growth by inducing ferroptosis.International journal of medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is linked to cardiovascular disease, cerebrovascular disease, diabetes, and dyslipidemia, lowering quality of life, work productivity, and healthcare expenditures. The aim of this present study is to investigate the mechanism of potato protein (PP) post-treatment in regulating lipogenesis and lipolysis in 3T3-L1 adipocytes. 9% PP hydrolysed for 2 h (PPH902) shows high yield and better activity; thus, PPH902 was used in all other experiments. 3T3-L1 preadipocyte cells were used, the cell culture medium were changed every 2 days, IDH was added on Day 0. PPH902 was added on the 8th day, it was left for 72 h and then cells are collected. The relative triglyceride residual (RTR) content was quantified, and the expression of key lipid metabolism-related proteins was analyzed using Western blotting. PPH902 at concentrations of 400 ppm, 800 ppm, and 1600 ppm markedly decreases the RTR content. PPH902, at higher doses, modulates the expression of lipid production-associated transcription factors PPARγ, SREBP-1c, and FAS by activating AMPK, which inhibits lipogenesis and activates phosphorylated HSL to enhance lipolysis, so augmenting lipid metabolism. These findings suggest that PPH902 is an effective anti-lipogenic and lipolysis-promoting agent with potential applications in anti-obesity interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.